Trial Profile
A Phase I, Randomized, Double-blind, Placebo Controlled, Single Dose Escalation Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BAY 866150 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Acronyms MATCHBOX
- Sponsors Bayer
- 22 May 2014 New trial record